Evidence for innate immune system activation in HIV type 1-infected elite controllers - PubMed (original) (raw)
Evidence for innate immune system activation in HIV type 1-infected elite controllers
Sonya Krishnan et al. J Infect Dis. 2014 Mar.
Abstract
Background: Elite controllers maintain high CD4(+) T-cell counts and suppress plasma human immunodeficiency virus (HIV) viremia in the absence of antiretroviral therapy (ART). It is unclear whether levels of biomarkers associated with coagulation, monocyte activation, and inflammation, which are linked to HIV-associated mortality, differ among elite controllers, ART recipients with suppressed viremia (plasma HIV type 1 RNA load, <50 copies/mL), and HIV-negative controls.
Methods: A total of 68 elite controllers, 68 ART recipients with suppressed viremia, and 35 HIV-negative participants were evaluated. Levels of biomarkers in cryopreserved plasma were measured by enzyme-linked immunosorbent assay and electrochemiluminescence-based assay. Cryopreserved peripheral blood mononuclear cells were used to assess monocyte phenotype and function and interferon-inducible gene expression (IFIG). Nonparametric testing was used to compare median values among groups.
Results: CD4(+) T-cell counts were similar between elite controllers and HIV-negative controls but significantly lower in ART recipients with suppressed viremia. Levels of C-reactive protein and interleukin 6 were higher and IFIG upregulated in both HIV-positive groups, compared with HIV-negative controls. D-dimer and soluble tissue factor levels were significantly elevated in elite controllers, compared with those in ART recipients with suppressed viremia and HIV-negative controls (P < .01). Monocytes from elite controllers (and ART recipients with suppressed viremia) expressed lower CCR2 and higher CX3CR1 levels than monocytes from HIV-negative controls. In addition, elite controllers had a significantly higher proportion of CD14(++)CD16(+) monocytes, compared with HIV-negative controls.
Conclusion: Elite controllers maintain control of plasma HIV viremia and have evidence of an activated innate immune response.
Keywords: Biomarkers; D-dimer; Elite Controllers; HIV; Monocytes; soluble Tissue Factor.
Figures
Figure 1.
Expression of interferon (IFN)–inducible genes in elite controllers, antiretroviral therapy recipients with suppressed viremia, and human immunodeficiency virus (HIV)–negative controls. See Methods for descriptions of participant groups. Gene expression was normalized to HIV-negative controls and 2 housekeeping genes. The asterisks denotes a P value of < .05, compared with HIV-negative controls, and the black bars denote statistically significant differences between the 2 HIV-positive groups by 1-way analysis of variance with corresponding P values as shown. Genes included are those expressing IFN-induced protein with tetratricopeptide repeats (IFIT) 1 and 3, chemokine C-C ligand 5 (CCL5), IFN-induced GTP-binding protein Mx (MX) 1 and 2, 2′-5′-oligoadenylate synthetase 2 (OAS2), signal transducers and activators of transcription 1 (STAT1), and IFN-γ (IFNG).
Figure 2.
Proportion of CD14++CD16+ (A), CCR2+ (B), and CX3CR1+ (C) monocytes in elite controllers, compared with antiretroviral therapy recipients with suppressed viremia and human immunodeficiency virus (HIV)–negative controls. See Methods for descriptions of participant groups. Comparisons were done between groups by the Mann–Whitney U test. Median values and interquartile ranges are indicated by bars.
Figure 3.
Proportion of tissue factor (TF)–expressing monocytes (A) and interleukin 1β (IL-1β)–expressing monocytes (B) in response to lipopolysaccharide (LPS) stimulation in elite controllers, compared with antiretroviral therapy (ART) recipients with suppressed viremia and HIV-negative controls. See Methods for descriptions of participant groups. Peripheral blood mononuclear cells were stimulated for 6 hours with LPS, treated with brefeldin A to block cytokine secretion, and then stained and fixed. Monocytes were gated as HLA-DR+ and lineage negative. Absolute increases in percentage of cells expressing TF (A) and IL-1β (B) in response to LPS stimulation were compared between the 3 groups by the Kruskal-Wallis test and then the Mann–Whitney U test for comparisons between 2 groups. Median values and interquartile ranges are indicated by bars.
Similar articles
- Is low-level HIV-1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?
Elvstam O, Medstrand P, Jansson M, Isberg PE, Gisslén M, Björkman P. Elvstam O, et al. HIV Med. 2019 Oct;20(9):571-580. doi: 10.1111/hiv.12756. Epub 2019 May 30. HIV Med. 2019. PMID: 31148335 - Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Hunt PW, et al. J Infect Dis. 2008 Jan 1;197(1):126-33. doi: 10.1086/524143. J Infect Dis. 2008. PMID: 18171295 Free PMC article. - Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.
Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, Önen NF, Kojic E, Patel P, Brooks JT, Sereti I, Baker JV; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) Investigators. Wilson EM, et al. J Infect Dis. 2014 Nov 1;210(9):1396-406. doi: 10.1093/infdis/jiu275. Epub 2014 May 9. J Infect Dis. 2014. PMID: 24813472 Free PMC article. - The Role of Innate Immunity in Natural Elite Controllers of HIV-1 Infection.
Shi Y, Su J, Chen R, Wei W, Yuan Z, Chen X, Wang X, Liang H, Ye L, Jiang J. Shi Y, et al. Front Immunol. 2022 Feb 8;13:780922. doi: 10.3389/fimmu.2022.780922. eCollection 2022. Front Immunol. 2022. PMID: 35211115 Free PMC article. Review. - Learning From the Exceptions: HIV Remission in Post-treatment Controllers.
Etemad B, Esmaeilzadeh E, Li JZ. Etemad B, et al. Front Immunol. 2019 Jul 24;10:1749. doi: 10.3389/fimmu.2019.01749. eCollection 2019. Front Immunol. 2019. PMID: 31396237 Free PMC article. Review.
Cited by
- Alterations of CCR2 and CX3CR1 on Three Monocyte Subsets During HIV-1/Treponema pallidum Coinfection.
Guo N, Chen Y, Su B, Yang X, Zhang Q, Song T, Wu H, Liu C, Liu L, Zhang T. Guo N, et al. Front Med (Lausanne). 2020 Jun 18;7:272. doi: 10.3389/fmed.2020.00272. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32626718 Free PMC article. - HIV-1 capsids from B27/B57+ elite controllers escape Mx2 but are targeted by TRIM5α, leading to the induction of an antiviral state.
Merindol N, El-Far M, Sylla M, Masroori N, Dufour C, Li JX, Cherry P, Plourde MB, Tremblay C, Berthoux L. Merindol N, et al. PLoS Pathog. 2018 Nov 12;14(11):e1007398. doi: 10.1371/journal.ppat.1007398. eCollection 2018 Nov. PLoS Pathog. 2018. PMID: 30419009 Free PMC article. - An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV.
Mystakelis HA, Wilson E, Laidlaw E, Poole A, Krishnan S, Rupert A, Welker JL, Gorelick RJ, Lisco A, Manion M, Baker JV, Migueles SA, Sereti I. Mystakelis HA, et al. AIDS. 2023 Oct 1;37(12):1827-1835. doi: 10.1097/QAD.0000000000003656. Epub 2023 Jul 24. AIDS. 2023. PMID: 37450602 Free PMC article. Clinical Trial. - Glycoproteomic study reveals altered plasma proteins associated with HIV elite suppressors.
Yang W, Laeyendecker O, Wendel SK, Zhang B, Sun S, Zhou JY, Ao M, Moore RD, Jackson JB, Zhang H. Yang W, et al. Theranostics. 2014 Sep 18;4(12):1153-63. doi: 10.7150/thno.9510. eCollection 2014. Theranostics. 2014. PMID: 25285165 Free PMC article. - Challenges and Promise of Human Immunodeficiency Virus Remission.
Li Y, Mohammadi A, Li JZ. Li Y, et al. J Infect Dis. 2021 Feb 15;223(12 Suppl 2):4-12. doi: 10.1093/infdis/jiaa568. J Infect Dis. 2021. PMID: 33586773 Free PMC article. Review.
References
- Hubert JB, Burgard M, Dussaix E, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS. 2000;14:123–31. - PubMed
- Goudsmit J, Bogaards JA, Jurriaans S, et al. Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS. 2002;16:791–3. - PubMed
- Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41:1053–6. - PubMed
- Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004;432:769–75. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials